CureVac N.V.

NASDAQ:CVAC  
14.21
+0.60 (+4.41%)
Earnings Announcements

Curevac Q1 Net Financial Result At EUR 0.1 Mln

Published: 05/25/2022 11:12 GMT
CureVac N.V. (CVAC) - Q1 Cash Position of EUR 658.2 Million As of March 31, 2022, Impacted by Wind-down Costs for First-generation Covid-19 Vaccine Program.
Q1 Operating Loss Amounted to EUR 15.3 Million for Three Months Ended March 31, 2022, Representing a Decrease of EUR 100.5 Million, From EUR 115.8 Million for Same Period in 2021.
Q1 Revenues Amounted to EUR 24.4 Million for Three Months Ended March 31, 2022, Representing an Increase of EUR 14.4 Million, Or 144%, From EUR 10.0 Million for Same Period in 2021.
Q1 Net Financial Result for Three Months Ended March 31, 2022, Was Positive With EUR 0.1 Million, Down EUR 3.5 Million From a Gain of EUR 3.6 Million for Same Periods in 2021.
Q1 Pre-tax Loss Was EUR 15.2 Million for Three Months Ended March 31, 2022, Compared to EUR 112.2 Million in Same Respective Period of 2021.
Revenue is expected to be $18.8 Million
Adjusted EPS is expected to be -$0.27

Next Quarter Revenue Guidance is expected to be $18.8 Million
Next Quarter EPS Guidance is expected to be -$0.33

More details on our Analysts Page.